Mogrify

Mogrify is a biotechnology company developing a novel class of in vivo reprogramming therapies for degenerative diseases.

Its proprietary platforms use large-scale transcriptomic and epigenomic network data to predict the transcription factors required to convert mature human cells directly into target therapeutic cell types without a stem cell intermediate.

The company's pipeline addresses ophthalmology, otology, and metabolic disease, and its platform is also licensed to biopharma partners for co-development.